Clearmind Biomedical, a leader in minimally invasive neurosurgical innovation, announced it has signed an exclusive US distribution agreement with Sutter Medical for the Neuroblade Multi-Function ...

New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil ...

Please provide your email address to receive an email when new articles are posted on . Beta-blocker use after heart attack in patients with preserved or mildly reduced heart function was assessed in ...

Apple introduced iOS 26 to the public at its annual Worldwide Developers Conference event in early June, and since then, has been polishing the software with developers for the eventual beta release.

This is the first in our four-part series on beta cell function and why it matters for detecting type 1 diabetes early. For people at risk for type 1 diabetes, assessing beta cells, which produce ...

Apple recently released its third developer beta for macOS Tahoe 26, but the release was struck by a small glitch. The interruption briefly delayed updates for Apple Silicon Macs. But all is well now, ...

Earlier today, Apple released its new set of developer betas, but a distribution issue affected the Apple Silicon version of macOS Tahoe 26 developer beta 3. Now, the issue seems to have been resolved ...

WASHINGTON, Feb. 24, 2025 /PRNewswire/ -- SoundExchange today announced that it has surpassed $12 billion in distributions to artists and rights owners since the company's inception in 2003. The ...

TIXiMED is developing TIX100, a proprietary non-immunosuppressive therapy that may become the first oral disease-modifying treatment option for people with type 1 diabetes The first-in-human, single ...

Investigators used MRI to evaluate brain perfusion in patients with transfusion-dependent (n=54) and non–transfusion-dependent (n=23) β-thalassemia versus 56 controls. They found that relative ...

HARTFORD, Conn.--(BUSINESS WIRE)--Virtus Convertible & Income Fund (NYSE: NCV) announced today that it has declared a $0.3515625 per share cash distribution payable on June 28, 2024 to Series A ...